Literature DB >> 16955969

Purification and kinetic studies on a circulating anticoagulant in a suspected case of lupus erythematosus.

E T Yin1, L W Gaston.   

Abstract

A circulating anticoagulant in a suspected case of lupus erythematosus has been highly purified by a combination of Sephadex gel filtration and DEAE cellulose chromatography. The inhibitor is a gamma globulin with a sedimentation coefficient of 6.6 Svedberg units. For its anticoagulant action, the lupus inhibitor requires a co-factor which is present both in the lupus and normal blood. The cofactor is located in the gamma globulins fraction which is relatively heat stable, but less than the inhibitor, at 56 degrees C. The active lupus inhibitor (inhibitor + cofactor) is not species specific against human prothrombin. Working with highly purified systems, the active inhibitor is found to inhibit prothrombin conversion by formed prothrombin activator. It does not appear to inhibit the formation of prothrombin activator nor does it affect purified prothrombin.

Entities:  

Mesh:

Substances:

Year:  1965        PMID: 16955969

Source DB:  PubMed          Journal:  Thromb Diath Haemorrh        ISSN: 0340-5338


  8 in total

Review 1.  Antigenic specificities of "antiphospholipid" autoantibodies.

Authors:  R A Roubey
Journal:  Springer Semin Immunopathol       Date:  1994

Review 2.  Antiphospholipid antibody syndrome: a review.

Authors:  P J Bingley; B I Hoffbrand
Journal:  J R Soc Med       Date:  1987-07       Impact factor: 5.344

3.  [Inhibitor of prothrombin activation].

Authors:  K Lechner; M Fischer; J Kühböck; C Steffen; W Waldhäusl
Journal:  Klin Wochenschr       Date:  1969-11-15

4.  Lupus anticoagulant after measles.

Authors:  W Muntean; W Petek
Journal:  Eur J Pediatr       Date:  1980-08       Impact factor: 3.183

Review 5.  The 'antiphospholipid syndrome' and the 'lupus anticoagulant'.

Authors:  J S Cameron; G Frampton
Journal:  Pediatr Nephrol       Date:  1990-11       Impact factor: 3.714

6.  Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant.

Authors:  M L Boey; C B Colaco; A E Gharavi; K B Elkon; S Loizou; G R Hughes
Journal:  Br Med J (Clin Res Ed)       Date:  1983-10-08

7.  Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients.

Authors:  R H Derksen; P Hasselaar; L Blokzijl; F H Gmelig Meyling; P G De Groot
Journal:  Ann Rheum Dis       Date:  1988-05       Impact factor: 19.103

8.  Prothrombin Is Responsible for the Lupus Cofactor Phenomenon in a Patient with Lupus Anticoagulant/Hypoprothrombinemia Syndrome.

Authors:  Vittorio Pengo; Lorena Zardo; Maria Grazia Cattini; Elisa Bison; Elena Pontara; Sara Altinier; Chunyan Cheng; Gentian Denas
Journal:  TH Open       Date:  2020-03-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.